Will muscle-boosting meds be the next big thing after GLP-1 drugs?

The desire for stronger, more muscular bodies has led to the development of muscle-boosting drugs, a pursuit that began in the 1990s. Researchers discovered a protein resembling growth factors that either enhance or inhibit cell growth. Mutating the gene to block this protein's function resulted in "mighty mice," showcasing double the usual muscle size. This discovery hinted that blocking myostatin in people could significantly increase muscle size.

Muscle mass is a balance between muscle-building factors, like growth factors released during exercise, and muscle-shrinking factors, such as myostatin. As people age, the balance shifts, making it increasingly challenging to maintain muscle mass. Maintaining mobility and preventing obesity are just two benefits of increased muscle mass.

Initial clinical trials showed promising results, but later trials have been less successful. One reason for this disappointment is that myostatin is not the only muscle-shrinking factor; activin A also binds to the same receptors as myostatin. Drugs that block myostatin or activin A can also affect other key growth factors, leading to undesirable side effects.

Researchers are exploring new approaches, such as blocking the receptors that myostatin and activin A bind to or targeting the precursor form of myostatin. Some companies are also investigating other methods that don't involve myostatin at all. Despite these efforts, concerns remain about the long-term use of myostatin-blocking drugs and their potential impact on the heart.

The success of GLP-1 weight-loss drugs has piqued interest in developing muscle-boosting drugs. However, GLP-1 drugs can lead to muscle loss, and individuals may struggle to regain muscle mass after discontinuing these drugs. Newer myostatin-targeting drugs are being tested in combination with GLP-1 drugs to potentially prevent muscle loss and enhance weight loss.